COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,673 Articles (22,913 medRxiv, 8,760 bioRxiv)

Most recent first Previous |  Page 1001: Articles 10001-10010  | Next

A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
Chupp, G., Spichler-Moffarah, A., Sogaard, O. S., Esserman, D., Dziura, J., Danzig, L., Chaurasia, R., Patra, K. P., Salovey, A., Nunez, A., May, J., Astorino, L., Patel, A., Halene, S., Wang, J., Hui, P., Patel, P., Lu, J., Li, F., Gan, G., Parziale, S., Katsovich, L., Desir, G., Vinetz, J. M.
10.1101/2022.01.28.22270035 — Posted: 2022-01-31 Discussion: Onsite
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
Hardt, K., Vandebosch, A., Sadoff, J., Le Gars, M., Truyers, C., Lowson, D., Van Dromme, I., Vingerhoets, J., Kamphuis, T., Scheper, G., Ruiz-Guinazu, J., Faust, S. N., Spinner, C. D., Schuitemaker, H., Van Hoof, J., Douoguih, M., Struyf, F.
10.1101/2022.01.28.22270043 — Posted: 2022-01-31
Virucidal activity and mechanism of action of cetylpyridinium chloride against SARS-CoV-2
Okamoto, N., Saito, A., Okabayashi, T., Komine, A.
10.1101/2022.01.27.477964 — Posted: 2022-01-31
High Frequencies of PD-1+TIM3+TIGIT+CTLA4+ Functionally Exhausted SARS-CoV-2-Specific CD4+ and CD8+ T Cells Associated with Severe Disease in Critically ill COVID-19 Patients
Coulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L., Nesburn, A. B., Kuppermann, B. D., BAHRAOUI, E., Vahed, H., Gil, D., Jones, T. M., Ulmer, J. B., BENMOHAMED, L.
10.1101/2022.01.30.478343 — Posted: 2022-01-31
Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies
Correa Giron, C., Laaksonen, A., Barroso da Silva, F. L.
10.1101/2022.01.29.478316 — Posted: 2022-01-31
Analysis of receptors responsible for the dysfunction of the human immune system by different viral infections
Ivanov, S. M., Tarasova, O. A., Poroikov, V. V.
10.1101/2022.01.26.477819 — Posted: 2022-01-31
In silico analysis of predicted differential MHC binding and CD8+ T-cell immune escape of SARS-CoV-2 B.1.1.529 variant mutant epitopes
Riesgo-Ferreiro, P., Ranganath, G., Bukur, T., Sorn, P., Rosler, T., Schrors, B., Lower, M.
10.1101/2022.01.31.478157 — Posted: 2022-01-31
HOW 1 CONCERNING IS A SARS-COV-2 VARIANT OF2 CONCERN? COMPUTATIONAL PREDICTIONS AND3 THE VARIANTS LABELING SYSTEM.
Ashoor, D., Marzouq, M., Trabelsi, K., Chlif, S., Abotalib, N., Ben Khalaf, N., Ramadan, A., FATHALLAH, D. M.
10.1101/2022.01.31.478425 — Posted: 2022-01-31
Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia
Kocher, J., Arwood, L., Roberts, R., Henson, I., Annas, A., Emerson, D., Stasko, N., Fulcher, M. L., Brotton, M., Randell, S. H., Cockrell, A.
10.1101/2022.01.25.477616 — Posted: 2022-01-31
Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants
Lee, I.-J., Sun, C.-P., Wu, P.-Y., Lan, Y.-H., Wang, I.-H., Liu, W.-C., Tseng, S.-C., Tsung, S.-I., Chou, Y.-C., Kumari, M., Chang, Y.-W., Chen, H.-F., Lin, Y.-S., Chen, T. -Y., Chiu, C.-W., Hsieh, C.-H., Chuang, C.-Y., Lin, C.-C., Cheng, C.-M., Lin, H.-T., Chen, W.-Y., Chiang, P.-C., Lee, C.-C., Liao, J. C., Wu, H.-C., Tao, M.-H.
10.1101/2022.01.31.478406 — Posted: 2022-01-31

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).